Generic Name and Formulations:
Auranofin 3mg; caps.
Prometheus Labs, Inc.
Indications for RIDAURA:
Active rheumatoid arthritis unresponsive to NSAIDs.
Initially 6mg daily in 1–2 divided doses. If response inadequate after 6 months, may increase to 3mg 3 times daily. If still ineffective after 3 months, discontinue.
History of gold-induced disorders.
Gold toxicity. Physicians should be experienced in chrysotherapy.
Be fully familiar with chrysotherapy and this product's toxicity and benefits before use. Impaired renal or hepatic function. Inflammatory bowel disease. Rash. History of bone marrow depression. Monitor CBC with differential, platelet count, urinalysis, renal, liver function and for GI bleeding. Discontinue immediately if thrombocytopenia, proteinuria, or hematuria occurs. Pregnancy (Cat.C), nursing mothers: not recommended.
DMARD (gold salt).
Bone marrow depression, proteinuria, hematuria, diarrhea, GI upset, ulcerative colitis, rash, pruritus, exfoliative dermatitis, stomatitis, conjunctivitis, proteinuria, nephrotic syndrome, cholestatic jaundice, gold bronchitis, pneumonitis, peripheral neuropathy.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Neuroimaging Markers of Bipolar Disorder Risk for At-Risk Youth
- Suicide Attempt Risk Among LGB Populations Higher Than Previously Estimated
- Residents Should Take Advantage of Paid Time Off
- Outpatient Engagement May Lower Suicide Attempts in Patients With Fibromyalgia
- Prevalence of Alzheimer Disease, Related Dementia Set to Double